Closed business combination with Panacea, yielding new public listing and strong cash position of approximately $830 million Patient enrollment ongoing in Phase 1/2 study of
Closed business combination with Panacea, yielding new public listing and strong cash position of approximately $830 million Patient enrollment ongoing in Phase 1/2 study of